Tejas Patil, Assistant Professor of Thoracic Oncology; Vice Head of Clinical Affairs, Division of Oncology, University of Colorado Anschutz, shared a post on X:
“It was an absolute pleasure to discuss treatment strategies for EGFR and HER2 NSCLC and importance of optimal biomarker testing in lung cancer earlier this year!
Watch the videos on Grace’s YouTube channel:
- Biomarkers and Targeted Therapies
- Treatments for EGFR NSCLC
- Treatments for HER2 NSCLC
- Real world biomarker testing.”
DESTINY-Lung03: T-DXd Confirms Activity in HER2-Overexpressing NSCLC, but Triplet Therapy Falls Short
